SoftBank Group Corp. (OTC:SFTBY) explored a potential takeover of U.S. chipmaker Marvell Technology Inc. (NASDAQ:MRVL) earlier this year, with the idea of combining it with Arm Holdings (NASDAQ:ARM), the UK chip designer that it controls, according to a report.Hardware Bet Amid AI BoomThe Japanese conglomerate’s CEO, Masayoshi Son, has been studying Marvell as a possible target on and off for years in a bid to beef up SoftBank’s hardware bet that can benefit from the artificial intelligence (AI) boom, Bloom ...

ConocoPhillips (NYSE:COP) will release earnings results for the third quarter before the opening bell on Thursday, Nov. 6.Analysts expect the Houston, Texas-based company to report quarterly earnings at $1.41 per share, down from $1.78 per share in the year-ago period. The consensus estimate for ConocoPhillips' quarterly revenue is $14.63 billion, compared to $13.6 billion a year earlier, according to Benzinga Pro.On Aug. 7, ConocoPhillips reported better-than-expected earnings for the second quarter.Shares ...

Earnings Report - ConocoPhillips is set to release its third-quarter earnings results on November 6, with analysts expecting earnings of $1.41 per share, a decrease from $1.78 per share in the same period last year [1] - The consensus estimate for quarterly revenue is $14.63 billion, up from $13.6 billion a year earlier [1] - The company reported better-than-expected earnings for the second quarter on August 7 [1] Stock Performance - Shares of ConocoPhillips fell by 0.2%, closing at $87.70 on Wednesday [2] Analyst Ratings - Susquehanna analyst Biju Perincheril maintained a Positive rating, lowering the price target from $113 to $110 [4] - Wells Fargo analyst Sam Margolin initiated coverage with an Equal-Weight rating and a price target of $100 [4] - Morgan Stanley analyst Devin McDermott maintained an Overweight rating, reducing the price target from $123 to $122 [4] - Raymond James analyst John Freeman maintained an Outperform rating, cutting the price target from $117 to $115 [4] - Melius Research analyst James West initiated coverage with a Hold rating and a price target of $117 [4]

Core Viewpoint - KKR & Co and Singapore Telecommunications are in advanced negotiations to acquire over 80% of ST Telemedia Global Data Centres, aiming for full ownership for more than S$5 billion (approximately $3.9 billion) [1] Group 1 - The acquisition would significantly enhance KKR & Co's and Singapore Telecommunications' presence in the data center sector [1] - The deal reflects the growing demand for data center services amid increasing digitalization and cloud computing trends [1] - This transaction is part of a broader trend of consolidation in the data center industry as companies seek to scale operations and improve service offerings [1]

Core Viewpoint - Commerzbank has raised its guidance for the year, anticipating continued support for its top line from increased income generated from loan interest [1] Group 1 - Commerzbank expects higher income from loans to positively impact its financial performance [1]

Core Insights - AstraZeneca exceeded third-quarter earnings expectations, driven by robust sales of key drugs for cancer, heart, and kidney diseases [1] Group 1: Financial Performance - The company reported strong earnings, surpassing market expectations for the third quarter [1] - Sales growth was particularly notable in the oncology, cardiovascular, and renal disease segments [1] Group 2: Market Position - AstraZeneca remains the most valuable listed company in London, reflecting its strong market position and investor confidence [1] - The performance reinforces AstraZeneca's strategic focus on high-demand therapeutic areas [1]

Group 1 - The article does not provide any specific information or insights regarding a company or industry [1]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Samsung Bioepis has entered into a settlement and license agreement with Johnson & Johnson for the commercialization of PYZCHIVA® in Europe [1] Company Summary - The agreement allows Samsung Bioepis to commercialize PYZCHIVA®, which is a biosimilar product, in the European market [1]

Core Points - VEON Ltd. has appointed Sebastian Rice as General Counsel, effective January 1, 2026, succeeding Vitaly Shmakov, who will become Chief Investment Officer [1][4] - Anand Ramachandran will continue as Chief Corporate Development Officer with expanded responsibilities in investor relations and value creation, also effective January 1, 2026 [2][4] - Sebastian Rice brings 24 years of experience from Akin Gump Strauss Hauer & Feld LLP, where he held significant leadership roles [2][3] - The leadership changes are part of VEON's strategy to enhance its digital operator transformation and drive growth in frontier markets [4] Company Overview - VEON is a digital operator serving over 150 million connectivity customers and approximately 120 million monthly active digital users [5] - The company operates in five countries, representing more than 6% of the global population, and is headquartered in Dubai [5] - VEON is listed on Nasdaq and aims to empower individuals and drive economic growth through technology-driven services [5]